SRR10842347
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.200
- SPERMATOGENESIS+0.200
- E2F_TARGETS+0.100
- G2M_CHECKPOINT+0.100
- KRAS_SIGNALING_DN+0.100
- DNA_REPAIR+0.000
- MYC_TARGETS_V1+0.000
- PI3K_AKT_MTOR_SIGNALING+0.000
- PROTEIN_SECRETION+0.000
- BILE_ACID_METABOLISM-0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- MYC_TARGETS_V2-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- ADIPOGENESIS-0.400
- ANGIOGENESIS-0.400
- APICAL_JUNCTION-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_61E80SD6 | medulloblastoma | — | 0.929 |
| 2 | SRR1457418 | GTEX | — | 0.926 |
| 3 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.925 |
| 4 | SRR1429935 | GTEX | — | 0.921 |
| 5 | SRR1402513 | GTEX | — | 0.918 |
| 6 | BS_KN92S7YQ | medulloblastoma | — | 0.917 |
| 7 | BS_2SFTWNVE | medulloblastoma | — | 0.913 |
| 8 | SRR1317808 | GTEX | — | 0.912 |
| 9 | SRR1460170 | GTEX | — | 0.912 |
| 10 | SRR10899998 | — | — | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |